

Curriculum Vitae – Short Version 2015-April 2021

I. Biographical Data

Name: James Duncan Kellner

Office Address: Department of Pediatrics
Alberta Children's Hospital
28 Oki Drive NW
Calgary, Alberta T3B 6A8

Contact: Telephone 403-955-5047 (direct)
403-955-7679 (research)
Email Jim.Kellner@albertahealthservices.ca

Citizenship: Canadian

Rank: Professor (with tenure)

Departments: Pediatrics,
Microbiology, Immunology and Infectious Diseases,
Community Health Sciences

Faculty: Cumming School of Medicine

Institutions: University of Calgary and
Calgary Zone, Alberta Health Services

II. Academic Record (All)

Final Degrees

1984 Doctor of Medicine, University of Calgary.
1998 Masters of Science (Clinical Epidemiology), University of Toronto.

Undergraduate

1981 Bachelor of Science (with Distinction), University of Alberta, Edmonton.

Graduate Training

1984-86 First and Second Year Pediatric Resident, Alberta Children's Hospital, Calgary.
1986-87 Post-Core Pediatric Resident, The Hospital for Sick Children, Toronto.
1987-88 Chief Pediatric Resident, The Hospital for Sick Children.
1988-89 Fellow in Emergency Pediatrics, The Hospital for Sick Children.
1993-95 Clinical Fellow in Pediatric Infectious Diseases, The Hospital for Sick Children.
1995-96 Research Fellow in Pediatric Infectious Diseases, The Hospital for Sick Children.
2019 Intermountain Healthcare Delivery Institute Advanced Training Program in Health Care Delivery Improvement, Salt Lake City, Utah.

Licensure and Boards

1988- Licentiate, The Medical Council of Canada.
1988- Fellow in Pediatrics, The Royal College of Physicians and Surgeons of Canada.
1988-97 General License, #57359, The College of Physicians and Surgeons of Ontario.

- 1990- License for Pediatrics, #010172, Alberta College of Physicians and Surgeons.
 1995- Certificate of Special Competence in Infectious Diseases, The Royal College of Physicians and Surgeons of Canada.

III. Awards and Distinctions (2015-2021)

- 2015 Canadian Association of Paediatric Health Centres (CAPHC) Board of Directors Appreciation Award for 6 year term on board.
 2016 Paediatric Chairs of Canada Appreciation Award for 3 year term as President.
 2017 Alberta Children's Hospital Medical Staff Association Physician of the Year Award.
 2018 Alberta Children's Hospital Foundation Board of Directors Appreciation Award for 10 year term on board.
 2019 American Academy of Pediatrics Special Achievement Award for Distinguished Service and Dedication to the Mission and Goals of the Academy.
 2019 Appointed to Alberta Children's Hospital Foundation Patron's Council.
 2020 Paediatric Chairs of Canada 2020 COVID Leadership Award.

IV. Academic and Hospital Appointments (All)

- 1989-90 Assistant Professor, Faculty of Medicine, Dept. of Pediatrics, University of Toronto.
 1989-90 Active Attending Medical Staff, Emergency Department, Hospital for Sick Children, Toronto.
 1990-93 Assistant Professor, Faculty of Medicine, Department of Pediatrics, University of Calgary.
 1990-93 Active Attending Medical Staff, Alberta Children's Hospital Emergency Department.
 1992-93 Acting Director, Emergency Department, Alberta Children's Hospital.
 1996-2000 Assistant Professor, Faculty of Medicine, Departments of Pediatrics and Microbiology and Infectious Diseases, University of Calgary.
 1996-99 Active Attending Medical Staff, Alberta Children's Hospital Emergency Department (part-time).
 1996- Consultant, Division of Infectious Diseases, Alberta Children's Hospital and Regional Division of Infectious Diseases, Calgary Health Region. Renamed Section of Infectious Diseases and Calgary Zone, Alberta Health Services, 2009.
 2000-05 Associate Professor, Faculty of Medicine, Departments of Pediatrics and Microbiology and Infectious Diseases, University of Calgary.
 2004-08 Head, Division of Pediatric Infectious Diseases.
 2005- Professor, Faculty of Medicine, Department of Pediatrics and Department of Microbiology and Infectious Diseases (renamed Microbiology, Immunology and Infectious Diseases in 2011), University of Calgary.
 2005-08 Deputy Head (Research and Administration), Department of Pediatrics.
 2007- Appointment with Tenure
 2008- Professor, Department of Community Health Sciences, University of Calgary.
 2008-18 Professor and Head, University of Calgary Department of Paediatrics and Regional Clinical Department Head Calgary Health Region Department of Pediatrics (renamed Calgary Zone, Alberta Health Services in 2009).

V. Educational Activities (2015-2021)

i. Undergraduate

- 2015 Supervisor summer student, Lauren Zwicker, St. Francis Xavier University on project: Correlation between invasive disease and nasopharyngeal colonization serotypes of *Streptococcus pneumoniae* in Calgary. Recipient of Maternal, Newborn, Child & Youth Strategic Clinical Network – ACHRI Scholars Training Program Summer Studentship.
- 2018-19 Supervisor, summer student, Julie-Anne Lemay, McMaster university on project: Homelessness in Adults with Invasive Pneumococcal Disease in Calgary.

ii. Graduate Teaching

- 2008- Lecturer, Infectious Diseases Subspecialty Residents/Fellows Core/Half-Day Lectures. Various topics: "Pneumococcal Infections" (2008), "Laryngitis, Croup, Epiglottitis & Bronchiolitis" (2014, 2016, 2018), "Immunizations", "COVID-19 Vaccines" (2021).

iib. Graduate Supervision and Mentorship

- 2012-15 Supervisor, Jason Cabaj, U of C Department of Community Health Science MSc, "Underlying Risk Conditions in Persons with Invasive Pneumococcal Disease Before and After the Introduction of Pneumococcal Conjugated Vaccines (PCVs)."
- 2012-17 Supervisor, Nicholas Conradi, on thesis project in King's College London Master of Public Health. "Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children, Before and After the 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada." Two abstract presentations (Canadian Immunization Congress, 2012 and International Symposium on Pneumococci and Pneumococcal Disease, 2014) and manuscript published, *PIDJ*, 2018.

iii. Postgraduate

- 2013-16 Co-Supervisor (with Dr. Suzanne Tough) of Dr. Shannon MacDonald for AI-HS Clinician Fellowship and CIHR Fellowship on project, "Do Current Immunization Delivery and Surveillance Systems Adequately Promote and Measure Uptake of the Measles, Mumps, Rubella and Varicella (MMR-V) Vaccine?"

iv. Continuing Education and Invited Addresses

- 2015
- Feb 24th Annual Paediatric Infectious Diseases Conference. "Impact of Pneumococcal Conjugate Vaccines on Burden of Diseases." Banff.
- Apr Snyder Institute Seminar Series, Cumming School of Medicine. "Prevention of Bacterial Infectious Through Integrated, Interdisciplinary Vaccine Design and Evaluation. (with Dr. Tony Schryvers). Calgary.
- 2016
- Dec 2016 Canadian Immunization Congress. "What's New in Pneumococcal Disease? Where Have We Been and Where are We Going?" Ottawa
- Dec 2016 Canadian Immunization Congress. Pfizer Research Exchange. "CASPER Update." Ottawa.
- 2017
- Feb Citywide Infectious Diseases Rounds. "What's New in Pneumococcal Disease?" Calgary
- Apr Snyder Research Institute Mini Medical School. "How Vaccines Have Improved the World." Calgary.
- Oct Ontario Public Health Special Seminar "What's New in Pneumococcal Disease? A View From the West." Toronto.

- Nov XXXIV Chilean Congress of Infectious Diseases. "Pneumococcal Disease Trends After Pneumococcal Conjugate Vaccines." Concepcion, Chile.
- Nov XXXIV Chilean Congress of Infectious Diseases. "Vaccine Hesitancy." Concepcion, Chile.
- 2018**
- Jan Western Canada Immunization Forum. "Expanded Use of PCV13 and PPV23." Vancouver.
- Jan BC Children's Hospital and UBC Vaccine Evaluation Centre and Vaccines, Infections and Host Defenses Joint Academic Rounds. "The Pneumococcus Today: Ever-Changing or, The More Things Change, The More They Stay the Same?" Vancouver.
- Nov Ibaraki Children's Hospital. "Pediatric Postgraduate Medical Education at Alberta Children's Hospital." Mito, Japan.
- Dec Association of Medical Microbiology and Infectious Diseases (AMMI) Symposium at Canadian Immunization Conference (CIC). "Impact of Pediatric Pneumococcal Immunization Programs in Canada." Ottawa.
- 2020**
- Apr Alberta Children's Hospital Grand Rounds: Donald Clogg Memorial Lecture in Pediatric Emergency Medicine. "COVID-19: Where We Are Now". Zoom seminar co-presented with Drs. Stephen Freedman (U of C) and Dan Fenster (Columbia-Presbyterian Hospital, New York City). Calgary.
- Apr University of Calgary Continuing Medical Education and Professional Development Webinar. "Care of the Pediatric Patient with COVID-19" co-presented with 11 others. Calgary.
- Apr Alberta Children's Hospital Foundation. "COVID-19 and the Alberta Children's Hospital", co-presented with Dr. Sid Viner and Ms. Margaret Fullerton. Calgary.
- May University of Calgary O'Brien Institute for Public Health Seminar. "Anatomy of a Pandemic: How COVID-19 is Impacting Children's Health and Social Wellbeing", co-presented with Dr. Deinera Exner-Cortens.
- Jun Paediatric Chairs of Canada Semi-Annual Meeting. "Fireside Chat on Leadership Pearls." Zoom Conference.
- Aug Calgary Emergency Management Agency. "Evidence to Inform School Reopening." Zoom Seminar with primary, secondary and post-secondary education leaders and civic service leaders from across Calgary.
- Sep University of Calgary Continuing Medical Education and Professional Development Webinar. "COVID Corner: School Opening and the Second Wave." Zoom Seminar presented with 3 others.
- Dec University of Calgary Continuing Medical Education and Professional Development Webinar. "COVID Corner: Hindsight 2020 – Lessons Learned and Moving Forward. COVID-19 Vaccines." Zoom Seminar presented with 3 others.
- Dec Canadian Paediatric Society (CPS) Symposium at Canadian Immunization Conference (CIC). "Pneumococcal Immunization in Children: Can We Do Better?" Zoom Seminar.
- Dec Alberta Children's Hospital Grand Rounds. "COVID-19 Update: What You Need to Know Now." Zoom seminar co-presented with Dr. Jessica Dunn.
- Dec Department of Critical Care Medicine Grand Rounds. "COVID-19 Vaccines: The Beginning of the End?" Zoom Seminar. Calgary.
- 2021**
- Jan AHS Medical Affairs Physician Community Conversation: Vaccination and COVID-19 Updates. "COVID-19 Vaccines." Provincial Zoom Seminar with 3 others and panel discussion.
- Jan Alberta Children's Hospital All Staff Town Hall. "COVID-19 Vaccines: Current Status and When Will They Get Us Out of the Pandemic?" Local Zoom Seminar. Calgary.
- Jan Citywide General Surgery Rounds. "COVID-19 Vaccines." Local Zoom Seminar. Calgary.

- Feb University of Calgary O'Brien Institute for Public Health Seminar. Anatomy of a Pandemic: Hopes and Challenges for the Coronavirus Vaccine. "COVID-19 Vaccines: Development, Efficacy and Safety." Provincial Zoom seminar co-presented with 3 others and panel discussion.
- Feb Foothills Medical Centre Operating Room Staff and Surgeon Rounds. "COVID-19 Vaccines: Current Status and When Will They Get Us Out of the Pandemic?" Local Zoom Seminar.
- Feb University of Calgary Graduate College. "COVID-19 Vaccines: Current Status and When Will They Get Us Out of the Pandemic?" Local Zoom Seminar. Calgary.
- Feb University of Calgary COVID Community. Keeping Your Kids Healthy and Happy During the Pandemic. "When Will Children Be Able to Get a COVID-19 Vaccine?" Local Zoom Seminar presented with 2 others and panel discussion.
- Mar Citywide Anesthesia Rounds. "COVID-19 Vaccines: Current Status and When Will They Get Us Out of the Pandemic?" Local Zoom Seminar. Calgary.
- Mar University of Calgary Continuing Medical Education and Professional Development Webinar. "COVID Corner: Vaccines versus Variants. COVID Corner Anniversary Edition." Provincial Zoom Seminar presented with 3 others and panel discussion.
- Mar Alberta Medical Association Representative Forum CME. "COVID-19 Vaccines" Provincial Zoom Seminar presented with 3 others and panel discussion. Calgary.
- Mar Department of Pediatrics Quarterly Meeting. "COVID-19 Vaccines: What's New ~~this Month Today~~ in the Last Hour?" Local Zoom Seminar. Calgary.
- Mar Royal College of Physicians and Surgeons of Canada Professional Practice Webinar. "COVID-19 Vaccination" National Webinar presented with Dr. Cora Constantinescu.
- Mar Alberta Children's Hospital All Staff Town Hall. "COVID-19 Vaccines: What's New ~~this Month Today~~ in the Last Hour?" Local Zoom Seminar. Calgary.
- Apr CanCOVID Workshop on COVID-19 Vaccines. Moderator for 4 speakers and discussant. National Zoom Seminar.
- Apr Snyder Institute for Chronic Diseases and Calgary Public Library Mini Medical School for the general public. "COVID-19 and its impact on children's immunity." Local Zoom seminar co-presented with Dr. Susa Benseler. Calgary.
- Apr Paediatric Chairs of Canada. "Career Transitions Workshop. National Zoom seminar, guest commentator with Dr. Janice Stein.
- Apr University of Calgary Hematology Rounds. "COVID-19 Vaccines, Variants and Implications for Your Patients." Local Zoom seminar. Calgary.
- Apr Citywide Infectious Diseases Rounds. "COVID-19 Vaccines: Overview and Current Controversies." Local Zoom Seminar. Calgary

VI. Administrative Responsibilities (All)

- i. Departmental**
- 1990-92 **Assistant Director**, Emergency Department, Alberta Children's Hospital.
- 1992-93 **Acting Director**, Emergency Department, Alberta Children's Hospital.
- 1996-02 Member, Child Health Research Unit Executive Committee.
- 1997-06 Member, Child Health Scientific Review Committee (**Chair** from 2001-2004, **Past Chair** 2004-06).
- 1998 Member, Academic Priorities Review Committee (*ad hoc*).
- 1999 Member, Clinical Teaching Unit Review Committee (*ad hoc*).
- 2000-05 Member, Child Health Research Centre Executive Committee (**Chair** from 2002-05).
- 2000-01 Member, Pediatric Residency Training Committee.
- 2000-04 **Director**, Pediatric Infectious Diseases PGME Fellowship Program.
- 2001-02 Member, Alternate Funding Plan Committee.

- 2002-18 Member, Alternate Funding Plan Steering Committee, **Chair** from 2007-08. Renamed AARP Management Committee in 2009
- 2002-08 **Chair**, Alternate Funding Plan Accountability Committee.
- 2003-05 Member, Institute of Maternal and Child Health Steering Committee.
- 2004-08 **Head**, Division of Pediatric Infectious Diseases.
- 2005-08 **Associate Director**, Institute of Maternal and Child Health.
- 2005-08 **Deputy Head** (Research and Administration), Department of Pediatrics.
- 2008-18 **Professor and Head**, Department of Pediatrics.
- 2008-18 **Chair**, Pediatric Executive Committee, renamed Zone Pediatric Executive Committee in 2011.
- 2008-15 Member, Childhood Cancer Collaborative Steering Committee.

ii. Faculty/University

- 1997-99 Faculty of Medicine Representative to Faculty of Social Work.
- 1997-98 Member, Selection Committee for Head, Department of Pediatrics.
- 1999-04 Member, Human Development Course Curriculum Committee (Infant, Child & Adolescent section).
- 1999-01 Member, Selection Committee for Pediatric Oncologist.
- 2000-04 Member, Student Academic Review Committee.
- 2002 **Chair**, Committee to Review Pediatric Clinical Clerkship Exam (*ad hoc*).
- 2005-10 Member, Institute of Maternal and Child Health Executive Committee. Renamed Alberta Children's Hospital Institute for Child and Maternal Health Leadership Council in 2009.
- 2005-08 Member, Student Affairs Committee.
- 2008-18 **Professor and Head**, Department of Paediatrics.
- 2008-18 Member, Faculty Leadership Forum.
- 2008-18 Member, Faculty Department Heads Committee.
- 2010-14 Member, Faculty Planning and Priorities Committee.
- 2012-13 **Chair**, Provincial Advisory and Operations Committee (PAOC) for the Province-wide Academic Alternate Remuneration Plan (P-AARP).
- 2016-18 Member, Academic Medicine Health Services Plan (AMHSP) South Sector Steering Committee.
- 2018- Member, Cumming School of Medicine Awards Committee.
- 2020- Member, University of Calgary COVID-19 Analytic and Strategy Group. Chaired by VP, Research.
- 2020- Member, Cumming School of Medicine Executive Faculty Council

iii. Calgary Health Region (to 2009)/Alberta Health Services – Calgary (2009 onwards)

- 1997-01 Member, Regional Blood Transfusion Committee.
- 1998 Member, Alberta Children's Hospital Isolation Unit Planning Group (*ad hoc*).
- 2000 Member, Public Health Laboratory User/Communication Group (*ad hoc*).
- 2001 Member, Pandemic Influenza Health Services Subcommittee.
- 2008-18 **Regional Clinical Department Head**, Pediatrics, renamed **Zone Clinical Department Head 2009**.
- 2008-18 Member, Regional/Zone Clinical Department Heads Committee.
- 2008-18 Member, Medical Advisory Board, renamed Zone Medical Advisory Committee in 2011.
- 2008-11 Member, AHS Women and Children's Integration Team, renamed Child Health Working Group 2009
- 2014-18 Member Alberta Children's Hospital Site Leadership Committee.

VII. Professional Activities (All)

i. Memberships

- 1984- Canadian Pediatric Society, Section on Emergency Pediatrics from 1989-99.
- 1984- Canadian Medical Protective Association, membership #705152.
- 1988- Canadian Medical Association, Alberta Medical Association from 1990.

- 1992- Alliance for the Prudent Use of Antibiotics.
- 1993- Pediatric Infectious Diseases Society.
- 1993- American Society for Microbiology.
- 1994- Canadian Infectious Diseases Society, renamed Association of Medical Microbiology and Infectious Disease Canada
- 1994- Infectious Diseases Society of America.
- 1997- Emerging Infectious Diseases Network.
- 2019- European Society for Paediatric Infectious Diseases.

ii. Professional Service

Grant Reviews

- 1997- Alberta Children's Hospital Foundation.
- 1997- The Hospital for Sick Children Foundation.
- 1999 Saskatchewan Health Services Utilization and Research Commission.
- 2000 Canadian Infectious Diseases Society.
- 2003- Physicians' Services Incorporated Foundation.
- 2004- Thrasher Foundation, Salt Lake City, Utah.
- 2005- Canadian Institutes of Health Research.
- 2005 Heart and Stroke Foundation of Canada.
- 2006 Canadian National Immunization Conference.

Grant Review Committees

- 1997-2009 Alberta Children's Hospital Foundation (Regular Grants & Small Grants).
- 2006 Canadian Institutes of Health Research (Microbiology & Infectious Diseases).
- 2006 Canadian Institutes of Health Research (Pandemic Influenza).
- 2007-15 Michael Smith Foundation for Health Research.
- 2015- Canadian Institutes of Health Research (Project Scheme).

Journal Reviews & Conference Abstract Reviews

- 1996 Archives of Pediatric and Adolescent Medicine.
- 1996-99 Canadian Journal of Infectious Diseases and Medical Microbiology.
- 1998 International Journal of Infectious Diseases.
- 1998- Pediatrics.
- 1998- Paediatrics and Child Health.
- 1999 Pediatric Research.
- 2000 Journal of American Medical Women's Association.
- 2001- Clinical Infectious Diseases.
- 2001-08 BioMedCentral.
- 2001- Journal of Infectious Diseases.
- 2001 Expert Opinion on Pharmacotherapy.
- 2002 Journal of Antimicrobial Chemotherapy.
- 2002-08 Journal of Clinical Microbiology.
- 2004- Pediatric Infectious Disease Journal.
- 2004-10 Antimicrobial Agents and Chemotherapy.
- 2004-08 Canadian Journal of Public Health.
- 2004 European Journal of Clinical Microbiology and Infectious Diseases.
- 2004 Canadian National Immunization Conference (abstract reviews).
- 2005 Pediatric Blood and Cancer.
- 2005-07 Clinical and Diagnostic Laboratory Immunology.

2007 Annals of Epidemiology.
 2010- Vaccine.
 2013- Journal of the Pediatric Infectious Diseases Society.
 2014- PLoS Medicine.
 2015- PLoS ONE.
 2018 Scientific Reports (A Nature journal).
 2018 Infection & Epidemiology.
 2019 PLoS Neglected Tropical Diseases.

Editorships

1998-2005 Editorial Group Member, Cochrane Collaboration Acute Respiratory Infections Review Group.
 2008-11 Editorial Board, Pediatric Infectious Disease Journal.
 2009-13 Associate Editor, Paediatrics, The Canadian Journal of Infectious Diseases and Medical Microbiology.

Community, Provincial, National & International Organizations

1990-95 Executive Committee, Canadian Pediatric Society Section on Emergency Pediatrics. **Vice-Chair**, 1992-1993.
 1991-96 Examiner, The Royal College of Physicians and Surgeons of Canada for Fellowship in Emergency Medicine.
 1998- Founder and PI, Calgary *Streptococcus pneumoniae* Epidemiology Research (CASPER) Team
 1998- Associate Investigator (Pneumococcal Project), Immunization Monitoring Program, Active (IMPACT).
 2000-03 Health Canada Population and Public Health Branch, Pandemic Influenza Contingency Planning: **Chair**, Clinical Subgroup; Member, Health Services Working Group.
 2001-03 Canadian Infectious Diseases Society Program Planning Committee.
 2001-04 Alberta Pandemic Influenza Contingency Planning: **Chair**, Clinical Subcommittee; Member, Health Services Subcommittee.
 2002-04 Member, Pediatric Infectious Diseases Society International Affairs Committee.
 2002-08 Member, Pediatric Investigators' Collaborative Network on Infections in Canada (PICNIC) Executive Committee.
 2002- Member, Alberta Health & Wellness Advisory Committee on Communicable Disease Control. Renamed Alberta Advisory Committee on Immunization 2010. Committee **Chair** from 2006 – 2016.
 2004-06 Fifth International Symposium on Pneumococci and Pneumococcal Diseases, International Scientific Committee.
 2006-09 Member, Pediatric Infectious Diseases Society Clinical Affairs Committee.
 2006-09 Member, National Centre for Streptococcus Scientific Advisory Committee.
 2007-10 Member, PneumoADIP (Pneumococcal Vaccine Accelerated Development and Implementation Plan) External Expert Committee to the Global Serotype Project.
 2007-14 Member, Canadian Association for Immunization Research and Evaluation (CAIRE) Steering Committee.
 2007-08 Member, National Advisory Committee on Immunizations (NACI).
 2008- Member, NACI Pneumococcal Working Group.
 2007-10 Member, External Expert Advisory Committee, Human Papillomavirus Vaccine Project, Michael Smith Foundation for Health Research, Vancouver.
 2008-18 Member, Alberta Children's Hospital Foundation Board of Directors. Member of Board subcommittees including Funding Priorities Committee and Funding Impact & Oversight Committee (formerly Letter of Intent Committee).
 2008-18 Member, Paediatric Chairs of Canada (Member, Executive Committee from 2009).
 2009-15 Member, Canadian Association of Paediatric Health Centres (CAPHC) Board of Directors.

- 2010- Founder and Co-PI Alberta Children's Hospital Infectious Diseases Epidemiology and Vaccine Evaluation (ACHIEVE) Team.
- 2010-12 Member, Public Health Agency of Canada Enhanced National Surveillance for Invasive Pneumococcal Disease Technical Advisory Committee.
- 2011-14 Member WHO Serotype Replacement Technical Advisory Group.
- 2011-13 **Vice-President**, Paediatric Chairs of Canada.
- 2013-16 **President**, Paediatric Chairs of Canada.
- 2016-18 **Past-President**, Paediatric Chairs of Canada.
- 2019- Member, Local Organizing Committee, 12th ISPPD (International Symposium on Pneumococci and Pneumococcal Diseases), Toronto, June 2020 (postponed to 2021).
- 2020- Member Leadership Group, Canadian COVID-19 Immunity Task Force.
Co-Chair, Field Studies Working Party.
- 2020- Member, Alberta COVID-19 Serology Advisory Group.
- 2020 External Reviewer, Department of Pediatrics, University of Ottawa and Children's Hospital of Eastern Ontario.
- 2021- Member, Data Safety Monitoring Board, VIDO sponsored COVID-19 vaccine clinical trial, "A Randomized, Observer-Blind, Dose-Escalation, Phase 1/2 Clinical Trial of COVAC Vaccines in Healthy Adults."
- 2021 Chair, External Review Committee, Department of Pediatrics, University of British Columbia and British Columbia Children's Hospital.

VIII. Research Support (2015-2021)

i. Peer-Reviewed Grants

2012-19

QUEST: Quadrivalent HPV Vaccine Evaluation Study.

Principal Investigators: G Ogilvie, S Dobson, M Krajden. **JD Kellner** (Site PI).

Funding: **\$3,200,000** Michael Smith Foundation for Health Research and Provincial Governments of British Columbia, Alberta, Quebec and Nova Scotia. (Local budget **\$99,300**.)

2014-19

Alberta Provincial Paediatric Enteric Infection Team (APPETTITE): Epidemiology, Emerging Organisms and Economics.

Collaborative Lead: SB Freedman. Collaborative Co-Leads: B Lee, M Louie, XL Pang. **JD Kellner** (Co-Investigator).

Funding: **\$4,998,400**. AIHS, CRIO Team.

2016-21

Enhancing HPV Vaccination in First Nations Populations in Alberta (EHVINA Study): Towards a Sustainable, Community-Driven, Knowledge Translation Strategy.

Collaborative Lead: G Nelson. Collaborative Co-Leads: A Letendre, S Tiwana, M Shea-Budgell. **JD Kellner** (Collaborative Member).

Funding: **\$1,248,000**. AIHS, Cancer Prevention Research Opportunity (CPRO).

2017-19

Prevention and Restriction of Antimicrobial Resistance in Pneumococci by Multi-Level Modelling (Restrict-Pneumo-AMR).

Consortium Coordinator: S Bentley (Wellcome Trust Sanger Institute). Principal Investigators: N. Fittipaldi, **JD Kellner**, B Schmeck, P Turner, T van der Poll

Funding: **\$2,218,689**. Joint Programming Initiative on Antimicrobial Resistance Team Grant (JPIAMR, CIHR and European Partners, \$400,000 from CIHR). (Local budget **\$250,000**.)

2017-19

Molecular Epidemiology of *Streptococcus pneumoniae* in Children with Pneumococcal Pneumonia in Canada between 1991 and 2016 and Implications for Future Vaccine Design.

Principal Investigator: M Sadarangani. Co-Investigators: J Zlosnick, J Bettinger, **JD Kellner**, O Vanderkooi, G Tyrrell.

Funding: **\$50,000**. BC Lung Association.

2017-2019

Childhood Immunization in Alberta First Nations People: Measurement of Coverage and Identification of Barriers and Supports.

Principal Investigators: SE MacDonald, LW Svenson, G Nelson. **JD Kellner** (Co-Investigator).

Funding: **\$199,768**. CIHR Improved Immunization Coverage Initiative.

2017-2021

Canadian Immunization Research Network.

Principal Investigators: SA Halperin and 20 others. **JD Kellner** (Co-Investigator, with 108 others).

Funding: \$10,083,333. CIHR and Public Health Agency of Canada.

2018-2020

A Randomized Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada.

Principal Investigators: M Sadarangani, OG Vanderkooi. Co-Investigators: J Bettinger, **JD Kellner**, J Langley, J Alcantara, J MacDonald, M Naus.

Funding: **98,674.50**. Alberta Children's Hospital Research Institute \$50,000.00 & Canadian Immunization Research Network \$48,674.50)

2018-2020

A Randomized Controlled Trial to Compare a 1-Dose vs 2-Dose Priming Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Canadian Infants.

Principal Investigators: M Sadarangani, OG Vanderkooi. Co-Investigators: **JD Kellner**, C Quach, J Langley, J MacDonald

Funding: **99,035.00**. Alberta Children's Hospital Research Institute \$50,000.00 & Canadian Immunization Research Network \$49,035.00)

2019-2021

The Benefits Of Pneumococcal Immunization Programs For Preventing Invasive Pneumococcal Disease, Acute Otitis Media, Community-Acquired Pneumonia In British Columbia And Ontario.

Principal Investigators: N. Crowcroft, F. Lawlji. Co-Investigators: **JD Kellner** (Co-Investigator with 10 others).

Funding: **\$304,682**. Canadian Immunization Research Network.

2019-2024

Contribution of the Microbiome to Asthma Risk in Premature Infants.

Principal Investigators: MC Arrieta-Mendez (nominated PI), M Azaf, G Giesbrecht, S Kembel, A Kozyrskyj, M Langille, K McNagny, L Sycuro. **JD Kellner** (Co-Investigator with 7 others).

Funding: **\$1,999,940**, with **\$566,667** from CIHR Team Grant: Canadian Microbiome Initiative 2: Research Teams.

2020-2022

COVID-19 Precision Health Genomics for Children: A Multiomic Study of the Alberta Childhood COVID-19 Cohort (AB3C) Study.

Principal Investigators: F Bernier, **JD Kellner**. Co-Investigators: M Esser, G Thompson, M Fritzler, M Croxen, N Forkert, S Benseler, B Berenger, J Blackwood, D Bulman, J Cabaj, A Eaton, E Castillo, C Constantinescu, W Dean, S Freedman, P Gordon, B Hallgrimsson, J Hu, F Jirik, P Kannu, S Kuhn, T Lacaze, R Lamont, Q Long, D Marshall, A Melin, R Newton, J Parboosingh, R Pon, J Robinson, S Taylor, M Twilt, G Vomiero, O Vanderkooi, G van Marle, E Wang.

Funding: **\$577,500**, with **\$287,500** from Genome Alberta COVID-19 Rapid Response Program Competition and remainder from intramural matching (**\$250,000** from Alberta Children's Hospital Research Institute, **\$40,000** from Mitogen).

2020-2022

Alberta Childhood COVID-19 Cohort (AB3C) Study.

Principal Investigators: F Bernier, **JD Kellner**. Co-Investigators: M Esser, G Thompson, M Fritzler, M Croxen, N Forkert, S Benseler, B Berenger, J Blackwood, D Bulman, J Cabaj, A Eaton, E Castillo, C Constantinescu, W Dean, S Freedman, P Gordon, B Hallgrimsson, J Hu, F Jirik, P Kannu, S Kuhn, T Lacaze, R Lamont, Q Long, D Marshall, A Melin, R Newton, J Parboosingh, R Pon, J Robinson, S Taylor, M Twilt, G Vomiero, O Vanderkooi, G van Marle, E Wang.

Funding: **\$750,506**, with **\$650,506** from Alberta Health for longitudinal sero-epidemiology study and **\$100,000** intramural matching from Alberta Children's Hospital Research Institute.

2020-2022

Canadian Immunization Research Network: COVID-19 Vaccine Readiness.

Principal Investigators: SA Halperin (Nominated PI), M Andrew, J Bettinger, S Bolotin, M Brisson, G De Serres, P De Wals, S Deeks, E Dubé, T Hatchette, JD Kellner, JC Kwong, JM Langley, MB Loeb, SE MacDonald, SA McNeil, KA Top, BJ Ward. Co-Investigators: 44 listed.

Funding: **\$3,516,000**. CIHR: COVID-19 Vaccine Readiness Funding Opportunity.

2020-2022

Epidemiology of Invasive Pneumococcal Disease, Effectiveness of New Generation Conjugate Vaccines And Potential of Future Vaccines in Canada.

Principal Investigator: P De Wals. Co-Investigators: N Brousseau, W. Demczuk, **JD Kellner**, I. Martin, A McGeer, M. Naus, M Sadarangani.

Funding: **\$305,576**. Canadian Immunization Research Network.

2021-2022

COVID-19 Knowledge Synthesis Network: COVID-19 Evidence Network to Support Decision-Making (COVID-END).

Principal Investigators: JN Lavis, JM Grimshaw, NA Santesso, AG Tricco. Co-Investigators: **Kellner JD** (and 90 others)

Funding: **\$1,000,000**. CIHR.

ii. Investigator Initiated Grants-in-Aid

2014-16

CASPER-PCV (Calgary Area *Streptococcus pneumoniae* Epidemiology Research-Pneumococcal Conjugate Vaccine) Study V – Continuation of Surveillance and Analysis of Invasive Pneumococcal Disease (IPD), Pneumococcal Related Disease (PRD) and Nasopharyngeal (NP) Colonization in Canada.

Investigators: **JD Kellner**, OG Vanderkooi, DL Church, J MacDonald.

Funding: **\$593,630**. Pfizer Pharmaceuticals (Investigator Initiated Research).

2017-19

CASPER-PCV (Calgary Area *Streptococcus pneumoniae* Epidemiology Research-Pneumococcal Conjugate Vaccine) Study VI – Surveillance and Analysis of Invasive Pneumococcal Disease (IPD), Pneumococcal Related Disease (PRD) and Nasopharyngeal (NP) Colonization in Canada.

Investigators: **JD Kellner**, OG Vanderkooi, J MacDonald.

Funding: **\$559,809**. Pfizer Pharmaceuticals (Investigator Initiated Research).

2019-22

CASPER-PCV (Calgary Area *Streptococcus pneumoniae* Epidemiology Research-Pneumococcal Conjugate Vaccine) Study VI Extension – Surveillance and Analysis of Invasive Pneumococcal Disease (IPD), Pneumococcal Related Disease (PRD) and Nasopharyngeal (NP) Colonization in Canada.

Investigators: **JD Kellner**, OG Vanderkooi, J Hu.

Funding: **\$787,004**. Pfizer Pharmaceuticals (Investigator Initiated Research).

iii. Contracts

2015 - 2017

A Phase IV, observer-blind, randomized, cross-over, placebo-controlled, multicenter study to assess the immunogenicity and safety of a single dose of Boostrix™ in pregnant women.

Investigators: Vanderkooi OG (Site Principal Investigator), **Kellner JD**, Kuhn SM, Wilson D, Dwinnell S, MacDonald J.

Funding: **\$199,076.80** GlaxoSmithKline (Contract).

2016 - 2018

Immunogenicity and safety study of GSK Biologicals' combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and *Haemophilus influenzae* type b vaccine (Infanrix hexa™) (217744) in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery.

Investigators: Vanderkooi OG (Site Principal Investigator), **Kellner JD**, Kuhn SM, Dwinnell S, MacDonald J.

Funding: **\$152,225.00** GlaxoSmithKline Biologicals. (Contract).

2017 - 2019

Immunogenicity and safety study of a booster dose of GSK Biologicals' combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and *Haemophilus influenzae* type b vaccine (Infanrix hexa™) (217744) in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery.

Investigators: Vanderkooi OG (Site Principal Investigator), **Kellner JD**, Kuhn SM, Dwinnell S, MacDonald J.

Funding: **\$100,000** GlaxoSmithKline. (Contract).

2019 – 2020

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator- controlled Study to Evaluate the Safety and Tolerability of V114-031 in Healthy Infants (PNEU – LINK, ClinicalTrials.gov Identifier: NCT03692871).

Investigators: **Kellner JD** (Site Principal Investigator), Constantinescu C, Hu J, Vanderkooi OG.

Funding: **\$345,045** Merck & Company (Contract).

2019 – 2021

A Phase III, Observer-Blind, Randomized, Multicountry Study to Assess the Reactogenicity and Safety of the Porcine Circovirus (PCV) Free Liquid Formulation of GSK's Oral Live Attenuated Human Rotavirus (HRV) Vaccine as Compared to the Lyophilized Formulation of the GSK's HRV Vaccine, When Administered as a 2-Dose Vaccination in Infants Starting at Age 6-12 Weeks (208236 ROTA-096, ClinicalTrials.gov Identifier: NCT03954743).

Investigators: **Kellner JD** (Site Principal Investigator), Hu J, Vanderkooi OG.

Funding: **\$120,770** GlaxoSmithKline Canada (Contract).

2021 – 2022

A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults. (MENB REC 2ND GEN-038 (V72_72), ClinicalTrials.gov Identifier: NCT04502693).

Investigators: **Kellner JD** (Site Principal Investigator), Dunn J, Constantinescu C, Vanderkooi OG.

Funding: **\$206,632** GlaxoSmithKline Canada (Contract).

IX. Publications (2021-2021, H-Index = 39)**i. Peer-Reviewed Manuscripts (Directly supervised trainees underlined, all references include, if available and in order of preference, DOI (Digital Object Identifier) or PMID (PubMed Central Indexing Number) or PMID (PubMed Indexing Number))**

92. Stearns JC, Davidson CJ, McKeon S, Whelan FJ, Shah ME, Schryvers AB, Bowdish DME, **Kellner JD**, Surette MG. Maturation of Bacterial Communities in the Upper Respiratory Tract. *The International Symposium on Microbial Ecology Journal (ISME J)* 2015;9(5):1246-59. (DOI:10.1038/ismej.2014.250)
93. Waye A, Chuck AW, Jacobs P, Tyrrell G, **Kellner JD**. Pevnar 7 Childhood Immunization Program and Serotype Replacement: Changes in Pneumococcal Incidence and Resulting Impact on Health Care Costs in Alberta (2003-2008). *Drugs – Real World Outcomes* 2015;2(2):153-161. Published online May 5, 2015; (DOI: 10.1007/s40801-015-0024-7)
94. Freedman SB, Lee BE, Louie M, Pang XL, Ali S, Chuck A, Chui L, Currie GR, Dickenson J, Drews SJ, Eltorki M, Graham T, Jiang X, Johnson DW, **Kellner JD**, Lavoie M, MacDonald J, MacDonald S, Svenson LW, Talbot J, Tarr P, Tellier R, Vanderkooi OG. Alberta Provincial Pediatric Enteric Infection TEam (APPETITE): Epidemiology, Emerging Organisms, and Economics. *BMC Pediatrics* 2015 Jul 31;15(1):89. (DOI 10.1186/s12887-015-0407-7, [Free PMC Article](#))
95. Bettinger JA, Rouleau I, Garipey MC, Bowie WR, Valiquette L, Vanderkooi OG, **Kellner JD**, Coleman BL, McNeil SA, McCarthy A, De Serres G, Public Health Agency of Canada/Canadian Institutes for Health Research Influenza Research Network (PCIRN). Successful Methodology for Large-Scale Surveillance of Severe Events Following Influenza Vaccination in Canada, 2011 and 2012. *Eurosurveillance* 2015 Jul 23;20(29):pii=21189. (DOI: 10.2807/1560-7917.es2015.20.29.21189, [Free Article](#))
96. Rajapakse N, Vayalunkal JV, Vanderkooi OG, Ricketson LJ, **Kellner JD**. Time to Reconsider Routine High-Dose Amoxicillin for Community-Acquired Pneumonia in All Canadian Children. *Paediatrics & Child Health* 2016;Mar 21(2):65-6 (DOI: 10.1093/pch/21.2.65, [Free PMC Article](#))
97. Freedman SB, Xie J, Neufeld MS, Hamilton WL, Hartling L, Tarr PI; Alberta Provincial Pediatric Enteric Infection Team (APPETITE, **Kellner JD** member). Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis. *Clinical Infectious Diseases* 2016 May 15;62(10):1251-8. (DOI: 10.1093/cid/ciw099, [Free PMC Article](#))
98. Cabaj JL, Nettel-Aguirre A, MacDonald J, Vanderkooi OG, **Kellner JD**. Influence of Childhood Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease (IPD) in Adults with Underlying Comorbidities in Calgary, Alberta (2000-2013). *Clinical Infectious Diseases* 2016;62(12):1521-6. (DOI: [10.1093/cid/ciw175](#))
99. Bettinger JA, Vanderkooi OG, Scheifele DW, Halperin SA, **Kellner JD**, Schryvers A, De Serres G, Alcantara J. Do Dose Numbers Matter? Evaluation of Differing Infant and Toddler Meningococcal C Conjugate Vaccine Programs in Canadian Children. *Pediatric Infectious Disease Journal* 2016;35(11):1242-6 (DOI: [10.1097/INF.0000000000001278](#))
100. Ricketson LJ, Conradi NJ, Vanderkooi OG, **Kellner JD**. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children, Before and After the 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada. *Pediatric Infectious Disease Journal* 2018;37(1):22-7. (DOI: [10.1097/INF.0000000000001709](#)).

101. Saini V, MacDonald SE, McNeil DA, McDonald SW, **Kellner JD**, Edwards SA, Stagg V, Tough S. Timeliness and Completeness of Routine Childhood Vaccinations in Children by Two Years of Age in Alberta, Canada. *Canadian Journal of Public Health* 2017;102(2):e124-8. (DOI: 10.17269/CJPH.108.5885)
102. Freedman SB, Xie J, Nettel-Aguirre A, Lee B, Chui L, Pang XL, Zhuo R, Parsons B, Dickenson JA, Vanderkooi OG, Ali S, Osterreicher L, Lowerison K, Tarr PI, Alberta Provincial Pediatric Enteric Team (APPETITE, **Kellner JD**, member). Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocculated swabs with stool specimens: an outpatient cohort study. *Lancet Gastroenterology & Hepatology*. 2017 Sep;2(9):662-9. (DOI: 10.1016/S2468-1253(17)30160-7, [Free PMC Article](#)).
103. Tang KL, Caffrey NP, Nóbrega DB, Cork SC, Ronksley PE, Barkema HW, Polachek AJ, Ganshorn H, Sharma N, **Kellner JD**, Ghali WA. Restricting the Use of Antibiotics in Food-Producing Animals and its Associations with Antibiotic Resistance in Food-Producing Animals and Human Beings: A Systematic Review and Meta-Analysis. *Lancet Planetary Health* 2017;1(1):317-27. (doi: 10.1016/S2542-5196(17)30141-9)
104. Mrklas KJ, MacDonald S, Shea-Budgell MA, Bedingfield N, Ganshorn H, Glaze S, Bill L, Healy B, Healy C, Guichon J, Colquhoun A, Bell C, Richardson R, Henderson R, **Kellner J**, Barnabe C, Bednarczyk RA, Letendre A, Nelson GS. Barriers, supports, and effective interventions for uptake of human papillomavirus- and other vaccines within global and Canadian Indigenous peoples: a systematic review protocol. *Systematic Reviews*. 2018 Mar 2;7(1):40.(doi: 10.1186/s13643-018-0692-y, [Free PMC Article](#)).
105. Henderson RI, Shea-Budgell M, Healy C, Letendre A, Bill L, Healy B, Bednarczyk RA, Mrklas K, Barnabe C, Guichon J, Bedingfield N, MacDonald S, Colquhoun A, Glaze S, Nash T, Bell C, **Kellner J**, Richardson R, Dixon T, Starlight J, Runner G, Nelson G. First nations people's perspectives on barriers and supports for enhancing HPV vaccination: Foundations for sustainable, community-driven strategies. *Gynecol Oncol*. 2018 Apr;149(1):93-100. (doi: 10.1016/j.ygyno.2017.12.024, [Free Article](#)).
106. Filler G, Kovesi T, Bourdon E, Jones SA, Givelichian L, Rockman-Greenberg C, Gilliland J, Williams M, Orrbine E, Piedboeuf B and Paediatric Chairs of Canada (**Kellner JD**, member). Does Specialist Physician Supply Affect Asthma Health Outcomes. *BMC Health Serv Res*. 2018 Apr 5;18(1):247. (doi: 10.1186/s12913-018-3084-z, [Free PMC Article](#))
107. McNeil DA, Mueller M, MacDonald S, McDonald S, Saini V, **Kellner JD**, Tough S. Maternal Perceptions of Childhood Vaccination: Explanations of Reasons For and Against Vaccination. *BMC Public Health*. 2019;19(1):49. (doi: 10.1186/s12889-018-6338-0.)
108. Tang KL, Caffrey NP, Nóbrega DB, Cork SC, Ronksley PE, Barkema HW, Polachek AJ, Ganshorn H, Sharma N, **Kellner JD**, Checkley SL, Ghali WA. Examination of Unintended Consequences of Antibiotic Use Restrictions in Food-Producing Animals: Sub-Analysis of a Systematic Review. *One Health*, 2019 May 15;7:100095 (doi: 10.1016/j.onehlt.2019.100095, [Free PMC Article](#))
109. Lemay JA, Ricketson LJ, Zwicker L, **Kellner JD**. Homelessness in Adults with Invasive Pneumococcal Disease in Calgary, Canada. *Open Forum Infectious Diseases*, 2019;6:10(October). (doi: 10.1093/ofid/ofz362.)
110. Tang KL, Caffrey NP, Nóbrega DB, Cork SC, Ronksley PE, Barkema HW, Polachek AJ, Ganshorn H, Sharma N, **Kellner JD**, Checkley SL, Ghali WA. Comparison of Different Approaches to Antibiotic Restriction in Food-Producing Animals: Stratified Results from a Systematic Review and Meta-Analysis. *BMJ Global Health*, 2019;4:e001710. (doi:10.1136/bmjgh-2019-001710)

111. Donken R, Dobson S, Marty K, Cook D, Sauvageau A, Gilca V, Dionne M, McNeil S, Kraiden Money MD, **Kellner JD**, Scheifele DW, Kollman T, Bettinger JA, Liu S, Singer J, Naus M, Sadarangani M, Ogilvie GS. Immunogenicity of 2 and 3 Doses of the Quadrivalent HPV Vaccine up to 10 Years Post-Vaccination; Follow-up of a Randomized Clinical Trial. *Clinical Infectious Diseases*, 2019 Sep 6. Pii: ciz887 (doi: 10.1093/cid/ciz887) (ePub ahead of print).
112. Ahmed MA, Naus M, Singer J, Valiquette L, Coleman BL, De Serres G, Vanderkooi OG, Top KA, Isenor JE, **Kellner JD**, McCarthy AE, Bettinger JA; Canadian Immunization Research Network (CIRN). Investigating the Association of Receipt of Seasonal Influenza Vaccine with Occurrence of Anesthesia/Paresthesia and Severe Headaches, Canada 2012/13-2016/17, the Canadian Vaccine Safety Network. *Vaccine*. 2020 Apr 23;39(19):3582-3590. doi: 10.1016/j.vaccine.2020.03.018. Epub 2020 Mar 27.
113. Bettinger JA, De Serres G, Valiquette L, Vanderkooi OG, **Kellner JD**, Coleman BL, Top KA, Isenor JE, McCarthy AE, on behalf of the Canadian Immunization Research Network (CIRN). 2017/18 and 2018/19 Seasonal Influenza Vaccine Safety Surveillance, Canadian National Vaccine Safety (CANVAS) Network. *Eurosurveillance* 2020;25(22) <https://doi.org/10.2807/1560-7917.ES.2020.25.22.1900470>.
114. MacDonald SE, Tough S, Guo X, **Kellner JD**. Impact of Combination MMRV Vaccine on First Dose Coverage and Use of Separate Vaccines: A Population-Based Study. *J Public Health (Berl.)* (2020). <https://doi.org/10.1007/s10389-020-01379-9>
115. Van Caesele P, Bailey D, Forgie SE, Dingle TC, Kraiden M, for the COVID-19 Immunity Task Force (**Kellner JD** member and author). SARS-CoV-2 (COVID-19) Serology: Implications for Clinical Practice, Laboratory Medicine and Public Health. *Can Med Assoc J* 2020 August 24;192:E973-9. <https://doi.org/10.1503/cmaj.201588>.
116. Nobrega DB, Tang K, Caffrey N, De Buck J, Cork S Ronksley P, Polachek A, Ganshorn H Sharma N **Kellner JD**, Ghali W, Barkema H. Prevalence of Antimicrobial Resistance Genes and its Association with Restricted Antimicrobial Use in Food-Producing Animals: A Systematic Review and Meta-Analysis. *Journal of Antimicrobial Chemotherapy* 2021 Feb 11;76(3):561-75. <https://doi.org/10.1093/jac/dkaa443>
117. Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, Cohen AL, Hetrich MK, Yang Y, Sinkevitch JN, Ampofo K, Aukes L, Bacci S, Bigogo G, Brandileone M-CC, Bruce MG, Camilli R, Castilla J, Chan G, Chanto Chacón G, Ciruela P, Cook H, Corcoran M, Dagan R, Danis K, de Miguel S, De Wals P, Desmet S, Galloway Y, Georgakopoulou T, Hammitt LL, Hilty M, Ho P-L, Jayasinghe S, **Kellner JD**, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, Lara CS, León ME, Lepp T, Mackenzie GA, Mad'arová L, McGeer A, Mungun T, Mwenda JM, Nuorti JP, Nzoyikorera N, Oishi K, De Oliveira LH, Paragi M, Pilishvili T, Puentes R, Rafai E, Saha SK, Savrasova L, Savulescu C, Scott JA, Scott KJ, Serhan F, Setchanova LP, Sinkovec Zorko N, Skoczynska A, Swarthout TD, Valentiner-Branth P, van der Linden M, Vestheim DF, von Gottberg A, Yildirim I, Hayford K, the PSERENADE Team. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. *Microorganisms*. 2021; 9(4):742. <https://doi.org/10.3390/microorganisms9040742>
118. Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, Peterson ME, Cohen AL, Almeida SCG, Ampofo K, Ang M, Bar-Zeev N, Bruce MG, Camilli R, Chanto Chacón G, Ciruela P, Cohen C, Corcoran M, Dagan R, De Wals P, Desmet S, Diawara I, Gierke R, Guevara M, Hammitt LL, Hilty M, Ho P-L, Jayasinghe S, Kleynhans J, Kristinsson KG, Ladhani SN, McGeer A, Mwenda JM, Nuorti JP, Oishi K, Ricketson LJ, Sanz JC, Savrasova L, Setchanova LP, Smith A, Valentiner-Branth P, Valenzuela MT, van der Linden M, van Sorge NM,

Varon E, Winje BA, Yildirim I, Zintgraff J, Knoll MD, the PSERENADE Team (**Kellner JD**, member). Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. *Microorganisms*. 2021; 9(4):738. <https://doi.org/10.3390/microorganisms9040738>

119. Bennett JC, Hetrich MK, Quesada MG, Sinkevitch JN, Knoll MD, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone M-CC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, Miguel Sd, Wals PD, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho P-L, Jayasinghe S, **Kellner JD**, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad'arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Muñoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Khan AS, Savrasova L, Scott JA, Skoczyńska A, Suga S, Linden Mvd, Verani JR, Gottberg Av, Winje BA, Yildirim I, Zerouali K, Hayford K, The PSERENADE Team. Changes in Invasive Pneumococcal Disease Caused by *Streptococcus pneumoniae* Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. *Microorganisms*. 2021; 9(4):696. <https://doi.org/10.3390/microorganisms9040696>

120. **Kellner JD**, Ricketson LJ, Demczuk WHB, Martin I, Tyrrell GJ, Vanderkooi OG, Mulvey MR. Whole Genome Phylogenetic Analysis and Clinical Features of *Streptococcus pneumoniae* Serotype 4 Causing an Outbreak of Invasive Pneumococcal Disease in Alberta, Canada. *Emerging Infectious Diseases* 2021 (Accepted for publication April 20, 2021).

ii. **Non Peer-Reviewed Manuscripts**

15. **Kellner JD** (invited editorial commentary). Who Benefits, and How Much? Indirect Effects of Childhood Pneumococcal Vaccination in Adults at Increased Risk of Pneumococcal Disease. *Clinical Infectious Diseases* 2019 Apr 15;68(8):1374-5 (<https://doi.org/10.1093/cid/ciy717>) (Published online 23 August 2018).

16. **Kellner JD** (report). Alberta Childhood COVID-19 Cohort (AB3C) Aim 3: Longitudinal Sero-Epidemiology Study First Interim Report January 31, 2021. *University of Calgary Libraries and Cultural Resources* <https://prism.ucalgary.ca/handle/1880/113084>

iv. **Abstracts (Directly supervised trainees underlined)**

115. Ogilvie GS, McNeil S, Sauvageau C, Gilca V, Mayrand MH, **Kellner JD**, Singer J, Money DM, Krjaden M, Dobson S. Quadrivalent Vaccine Evaluation Study (QUEST): Longitudinal Study Evaluating Effectiveness of Reduced Dosing of the Quadrivalent HPV Vaccine (Q-HPV). Poster presentation at 30th International Papillomavirus Conference (IPVC) 2015. Lisbon, Portugal. September 2015.

116. Ricketson LJ, Nettel-Aguirre A, Vanderkooi OG, **Kellner JD**, for the CASPER Investigators. Pneumococcal Disease Trends in the Post-Vaccine Era in Calgary, Canada: An Interrupted Time Series Analysis. Poster presentation #049 at 10th ISPPD, Glasgow, Scotland, June 2016.

117. Ricketson, LJ, Pyra S, Vanderkooi OG, **Kellner JD**, for the CASPER Investigators. Pneumococcal Serotypes Causing Invasive Disease Among Homeless Adults in Calgary, Alberta: Another Outbreak Emerging? Poster presentation #621 at 10th ISPPD, Glasgow, Scotland, June 2016.

118. Ricketson LJ, McGeer A, Rudnick W, Green K, Vanderkooi OG, **Kellner JD**, for TIBDN and CASPER Investigators. Pneumococcal Serotypes Causing Invasive Disease Post –PCV13: A Tale of Two Canadian Cities. Poster presentation #393 at 10th ISPPD, Glasgow, Scotland, June 2016.

119. Mueller M, MacDonald S, McDonald S, Saini V, **Kellner JD**, Tough S, McNeil DA. Maternal Perceptions of Childhood Vaccination: Reasons For and Against. Poster presentation at Canadian Immunization Conference, Ottawa, December, 2016.
120. Bettinger JS, Scheifele DW, Halperin SA, **Kellner JD**, Vanderkooi OG, Schryvers A, De Serres G, Alcantara J. Evaluation of Meningococcal C Conjugate Vaccine Programs in Canadian Children: Duration of Protection. Oral presentation at Canadian Immunization Conference, Ottawa, December, 2016.
121. Ricketson LJ, Vanderkooi OG, Pyra SN, MacDonald JC, **Kellner JD** for CASPER investigators. Persistence of Vaccine Serotypes Causing Invasive Pneumococcal Disease after Introduction of the 13 Valent Vaccine in Calgary, Canada. Poster presentation at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia. April, 2018.
122. Ricketson LJ, Pyra SN, Gray JD, Vanderkooi OG, MacDonald JC, **Kellner JD**. Point Prevalence Survey of Asymptomatic Nasopharyngeal Colonization by *Streptococcus pneumoniae* in Older Adults in Calgary, Canada. Poster presentation at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia. April, 2018.
123. Bettinger JA, Sadarangani M, Morris SK, **Kellner JD**, Le Saux N, Embree J, Vanderkooi OG, Martin I, Demczuk W, Tyrrell GJ, Vaudry W, Halperin S on behalf of the members of the Canadian Immunization Program, Active. Twenty-Six Years of Invasive Pneumococcal Disease in Canadian Children, 1991-2016, the Canadian Immunization Monitoring Program, Active. Platform presentation at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia. April, 2018.
124. Sadarangani M, Morris SK, **Kellner JD**, Le Saux N, Embree J, Vanderkooi OG, Martin I, Demczuk W, Tyrrell GJ, Vaudry W, Halperin S, Bettinger JA for the members of the Canadian Immunization Program, Active. Clinical features and outcomes of invasive pneumococcal disease in Canada between 1991 and 2015. Platform presentation at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia. April, 2018.
125. **Kellner JD**, Ricketson LJ, Vanderkooi OG, Tyrrell G, Demczuk WHB, Martin I. Whole Genome Phylogenetic Analysis of *Streptococcus Pneumonia* a Causing an Outbreak of Serotype 4 Invasive Pneumococcal Disease (IPD) in Alberta, Canada. Platform presentation at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Melbourne, Australia. April, 2018.
126. Marty K, Donken R, Sadarangani M, Cook D, Dobson S, Kraiden M, Mayrand MH, Sauvageau C, Gilca V, McNeil S, **Kellner JD**, Ogilvie G. No Prevalent HPV16/18 Infectious After Two Doses of HPV Vaccine in Girls; An Interim Analysis from the Quadrivalent HPV Vaccine Evaluation Study. Poster presentation at the 36th European Society for Pediatric Infectious Diseases, Malmo, Sweden. May 2018.
127. Lemay JA, Zwicker LR, Ricketson LJ, Vanderkooi OG, MacDonald JC, **Kellner JD**. Homelessness and Invasive Pneumococcal Disease (IPD) in Calgary: Both PCV13 and PPV23 Vaccines Should Be Given to This Population. Poster presentation at the Alberta Children's Hospital Research Institute Student's Research Day. Calgary, AB. August, 2018.
128. Donken R, Sadarangani M, Cook D, Marty K, Dobson S, Kraiden M, Mayrand MH, Sauvageau C, Gilca V, McNeil S, **Kellner JD**, Ogilvie G. After a Two-Dose Schedule in Girls No Prevalent HPV16/18 Infectious Were Found; An Interim Analysis from the Quadrivalent HPV Vaccine Evaluation Study. Poster presentation at 32nd International Papillomavirus Conference (IPVC) 2018. Sydney, Australia. October 2018.

129. Marty K, Donken R, Sadarangani M, Cook D, Dobson S, Kraiden M, Mayrand MH, Sauvageau C, Gilca V, McNeil S, **Kellner JD**, Ogilvie G. No Prevalent HPV16/18 Infections After Two Doses of HPV Vaccine in Girls; An Interim Analysis from the Quadrivalent HPV Vaccine Evaluation Study. Poster presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
130. Ahmed M, Valiquette L, Coleman B, De Serres G, Vanderkooi O, Top K, Isenor J, **Kellner JD**, McCarthy A, Singer J, Naus M, Bettinger J. Investigating the Effect Of Seasonal Influenza Vaccination On The Development Of Anesthesia/Paresthesia, Headaches And Generalized Convulsive Seizures, Canada 2012-2016. Poster presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
131. Sadarangani M, Morris SK, **Kellner JD**, Le Saux N, Embree J, Vanderkooi OG, Martin I, Demczuk W, Tyrrell GJ, Vaudry W, Halperin S, Bettinger JA for the members of the Canadian Immunization Program, Active. Clinical features and outcomes of invasive pneumococcal disease in Canada between 1991 and 2015. Oral presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
132. Bettinger JA, Sadarangani M, Morris SK, **Kellner JD**, Le Saux N, Embree J, Vanderkooi OG, Martin I, Demczuk W, Tyrrell GJ, Vaudry W, Halperin S on behalf of the members of the Canadian Immunization Program, Active. Twenty-Six Years of Invasive Pneumococcal Disease in Canadian Children, 1991-2016, the Canadian Immunization Monitoring Program, Active. Poster presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
133. **Kellner JD**, Ricketson L, Vanderkooi O, MacDonald J. Persistence of Vaccine Serotypes Causing Invasive Pneumococcal Disease after Introduction of the 13-Valent Vaccine in Calgary, Canada. Poster presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
134. **Kellner JD**, Ricketson L, Pyra S, Gray J, Vanderkooi O, MacDonald J. Whole Genome Phylogenetic Analysis of Streptococcus Pneumoniae Causing an Outbreak of Serotype 4 Invasive Pneumococcal Disease (IPD) in Alberta, Canada. Poster presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
135. Coleman B, DeSerres G, McCarthy A, Isenor J, Top K, Valiquette L, Vanderkooi O, **Kellner J**, Tai C, Bettinger J. Recurrent Adverse Events Following Vaccination with Influenza Vaccine Can Lead to Vaccine Hesitancy in Adults: CANVAS 2017/18 results from the Canadian Immunization Research Network. Oral presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
136. Ahmed M, Valiquette L, Vanderkooi O, Coleman B, De Serres G, Top K, Isenor J, **Kellner J**, McCarthy A, Singer J, Naus M, Bettinger J. Investigating the Effect of Seasonal Influenza Vaccination on the Development of Anesthesia/Paresthesia, Headaches, and Seizures, Canadian Immunization Research Network (CIRN), 2012-2016. Poster presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
137. Donken R, Dobson S, Marty K, Cook D, Sauvageau C, Gilca V, Dionne M, McNeil S, Kraiden M, Money D, **Kellner J**, Scheifele D, Kollman T, Bettinger J, Singer J, Naus M, Sadarangani M, Ogilvie G. Immunogenicity of Two Compared with Three Doses of the Quadrivalent HPV Vaccine up to 10 Years Postvaccination: Phase III Post-licensure Randomized Trial. Oral presentation at the Canadian Immunization Conference. Ottawa, ON. December, 2018.
138. Lemay JA, Zwicker LR, Ricketson LJ, Vanderkooi OG, MacDonald JC, **Kellner JD**. Homelessness and Invasive Pneumococcal Disease (IPD) in Calgary: Both PCV13 and PPV23 Vaccines Should Be Given to This Population. Poster presentation at the Canadian Association for Immunization Research and Evaluation Annual Meeting. Ottawa, ON. December, 2018.

v. Communications

40. Desai S, Quach-Thanh C, Caya C, Boikos C for the National Advisory Committee on Immunization (NACI). An Advisory Committee Statement: Re-Immunization with Polysaccharide 23-Valent Pneumococcal Conjugate Vaccine (Pneu-P-23). Public Health Agency of Canada, July 2016, ISBN 978-0-660-05015-7. (**Kellner JD** acknowledged for contribution.)
41. Baclic O, Quach C, Winters N for the National Advisory Committee on Immunization (NACI). An Advisory Committee Statement: Update on the Use of 13-Valent Pneumococcal Conjugate Vaccine (PNEU-C-13) in Addition to 23-Valent Pneumococcal Polysaccharide Vaccine (PNEU-P-23) in Immunocompetent Adults 65 Years of Age and Older – Interim Recommendation. Public Health Agency of Canada, October 2016, ISBN 978-0-660-05838-2. (**Kellner JD** acknowledged for contribution.)
42. Quach C, Baclic O, on behalf of the National Advisory Committee on Immunization (NACI). Summary of NACI Statement: Interim Recommendations on the Use of Pneumococcal Vaccines in Immunocompetent Adults 65 Years of Age and Older. *Can Comm Dis Rep.* 2016;42(12):260-2. (**Kellner JD** acknowledged for contribution as Working Group member.)
43. Doig CJ, Solverson KJ. A Fatal Case of Pneumococcal Sepsis Years After Splenectomy. *Canadian Medical Association Journal* 2017 Jun 12;189(23):E800-2. DOI: 10.1503/CMAJ.160455 (**Kellner JD** acknowledged for contribution.)
44. Kraicer-Melamed H, Baclic O, De Wals P, Quach C, Chevalier T, Moffatt C. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Update on the use of pneumococcal vaccines in adults 65 years of age and older – A Public Health Perspective. Public Health Agency of Canada, October 2016, ISBN 978-0-660-27296-2. (**Kellner JD** acknowledged for contribution.)